berlition has been researched along with celecoxib in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dannhardt, G; Scholz, M; Ulbrich, HK | 1 |
Dannhardt, G; Lindbom, L; Mattern, A; Scholz, M; Soehnlein, O; Ulbrich, HK | 1 |
Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
3 other study(ies) available for berlition and celecoxib
Article | Year |
---|---|
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
Topics: Azoles; Cyclooxygenase Inhibitors; Free Radical Scavengers; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Models, Molecular; Selenium Compounds | 2008 |
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Free Radical Scavengers; Hydroxyl Radical; Lipoxygenase Inhibitors; Macrophage-1 Antigen; Mice; Neutrophils; Peritonitis; Sulfhydryl Compounds; Thiazoles | 2009 |
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |